What it is
This is a single vial containing two compounds mixed together: Cagrilintide, a long-acting amylin analogue, and GLP1-S, a GLP-1 receptor agonist. Both are at 5 mg, so the vial holds 10 mg of peptide in total.
Taking the words apart. Amylin is a hormone released by the pancreas at the same time as insulin; it controls appetite, fullness, and blood sugar. GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases when you eat, which suppresses appetite. An agonist or analogue is something that copies a hormone and switches on the same receptors.
The point of combining them is that they work through different pathways, so the effects add up. The results are comparable to GLP2-T, but reached through this dual mechanism instead.
What each side does:
Cagrilintide is a stabilised amylin analogue that resists being broken down by enzymes, which is what makes its effects last. It induces satiety — the feeling of having had enough — and reduces food intake; suppresses glucagon, the hormone that raises blood sugar; slows stomach emptying, which prolongs fullness; promotes vasodilation, the widening of blood vessels, improving circulation; and supports bone health by reducing the activity of osteoclasts, the cells that break bone down, while increasing the activity of osteoblasts, the cells that build it up.
GLP1-S suppresses appetite through signalling in the hypothalamus, a control centre near the base of the brain; reduces glucagon secretion; delays stomach emptying; and aids glucose regulation.
The second component is sometimes misspelled "Cagrilinitide"; the correct spelling is Cagrilintide.
A fixed 5 mg / 5 mg co-formulation of cagrilintide, a long-acting amylin analogue, and GLP1-S, a GLP-1 receptor agonist — 10 mg of total peptide per vial.
The rationale is mechanistic non-overlap: amylin and incretin are separate axes, so the effects are additive rather than competing for the same receptor pool. The outcome is framed as comparable to tirzepatide-class results achieved through a synergistic dual mechanism.
Cagrilintide arm: stabilised amylin analogue resistant to enzymatic degradation, hence the prolonged action. Induces satiety and reduces food intake; suppresses glucagon; delays gastric emptying; promotes vasodilation with improved circulation; supports bone via reduced osteoclast and increased osteoblast activity.
GLP1-S arm: hypothalamic appetite suppression; reduced glucagon secretion; delayed gastric emptying; glucose regulation.
Outcomes cited: 23–24.4% average total body weight loss, against 15–17% for GLP1-S alone; comparable to GLP2-T; greater than either component individually. Possible support for bone density, cardiovascular health, and glucose control.
The critical dosing caveat is the starting point: even users transferring from GLP1-S or another GLP must start at the lowest dose, because the cagrilintide component is potent and has to be introduced low and slow.
The amylin component is sometimes misspelled "Cagrilinitide".
What it does
Weight: the reported average is 23–24.4% total body weight loss, compared with 15–17% for GLP1-S used on its own. That is comparable to the weight loss achieved with GLP2-T, and greater than using either of the two components individually.
Appetite: both components suppress appetite, and both slow stomach emptying so that fullness lasts longer after a meal.
Blood sugar: both suppress glucagon, the hormone that raises blood sugar, and both aid glucose regulation.
Beyond weight: it may support bone density, cardiovascular health, and glucose control. The cagrilintide component also promotes vasodilation, which improves circulation.
Body composition: 23–24.4% average total body weight loss, against 15–17% for GLP1-S monotherapy; comparable to GLP2-T; superior to either component alone.
Appetite and gastric: dual appetite suppression — hypothalamic from the GLP-1 arm, amylin-receptor from the cagrilintide arm — with additive delay of gastric emptying.
Glycaemic: glucagon suppression from both arms plus glucose regulation.
Secondary: possible support for bone density, cardiovascular health, and glucose control; vasodilation and improved circulation from the amylin component; bone remodelling shifted toward formation via reduced osteoclast and increased osteoblast activity.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Average 23–24.4% total body weight loss, against 15–17% with GLP1-S alone.Human trials
- Comparable to the weight loss achieved by GLP2-T.Limited human data
- Greater effect than using either compound on its own.Human trials
- May support bone density.Animal or lab only
- May support cardiovascular health.Human trials
- May support glucose control.Human trials
- Induces satiety and reduces food intake.Human trials
- Suppresses glucagon, the hormone that raises blood sugar.Limited human data
- Slows stomach emptying, so fullness lasts longer.Limited human data
- Promotes vasodilation — widening of blood vessels — which improves circulation.Animal or lab only
- Supports bone by reducing the cells that break bone down and increasing the cells that build it up.Animal or lab only
- 23–24.4% average total body weight loss versus 15–17% for GLP1-S alone.Human trials
- Comparable outcome to GLP2-T through a mechanistically distinct route.Limited human data
- Greater than either component individually.Human trials
- May support bone density, cardiovascular health, and glucose control.Animal or lab only
- Dual satiety induction with reduced food intake.Human trials
- Glucagon suppression from both arms.Limited human data
- Additive delay of gastric emptying.Limited human data
- Vasodilation with improved circulation.Animal or lab only
- Bone remodelling shifted toward formation: reduced osteoclast, increased osteoblast activity.Animal or lab only
Reconstitution and dosing
One vial size: 5 mg of each compound — 10 mg of peptide in the vial altogether — mixed with 1.5 mL (150 units) of bacteriostatic water. "Units" means the marks on an insulin syringe — 100 units is 1 mL. That works out to about 67 mcg of blend per unit, which is 33 mcg of each compound.
Inject under the skin, once a week, on the same day each week.
Start at the lowest dose even if you are transferring from GLP1-S or another GLP. This is essential, because the cagrilintide component is potent and has to be introduced slowly.
The titration is four weeks per step: 0.25 mg for weeks 1–4, 0.5 mg for weeks 5–8, 0.75 mg for weeks 9–12, and 1 mg for weeks 13–16. After that, increase weekly as tolerated in 0.25 mg steps until you reach the maximum target dose of 2.5 mg. Each dose figure refers to the amount of each of the two compounds, since they are present in equal amounts — so a 0.25 mg step means 0.25 mg of each, and 0.5 mg of blend drawn out of the vial. The doses in the table below are given as the total blend drawn, with the per-compound amount in the row label.
One caution about the numbers. You may see unit figures such as "5 units = 0.25 mg"; those only work out if 5 mg is mixed with 1 mL, not with the 1.5 mL used here. With the stated 1.5 mL, 0.25 mg of each compound is 0.5 mg of blend, which is 0.075 mL — 7.5 units, not 5. The draw volumes shown below are calculated from the stated 1.5 mL, so they are 1.5 times those figures at every step. If you want the milligram doses the schedule names, use the draws shown below.
Storage: keep it refrigerated, do not freeze, and it keeps for up to 12 months when properly stored.
Single presentation: 5 mg cagrilintide + 5 mg GLP1-S — 10 mg total peptide — reconstituted in 1.5 mL (150 units) of bacteriostatic water. That is 6.67 mg/mL of blend, 66.7 mcg of blend per insulin unit, 33.3 mcg of each arm. Subcutaneous, weekly, fixed day.
Dose semantics. The titration figures are per component: "0.25 mg" is 0.25 mg of GLP1-S and 0.25 mg of cagrilintide, so 0.5 mg of blend is drawn. The schedule below states the drawn blend mass, with the per-component dose in each row label, and the draw volumes are computed against the 10 mg vial total.
Unit-table discrepancy — read before dosing. Circulating titration tables for this blend state 5 units = 0.25 mg, 10 units = 0.5 mg, and so on. Those figures correspond to 5 mg of one component in 1 mL, not to the 1.5 mL specified here. At the stated 1.5 mL, 0.25 mg of each component is 0.5 mg of blend = 0.075 mL — 7.5 units, not 5; 2.5 mg of each is 5 mg of blend = 75 units, not 50. The draws below are computed from the stated diluent volume and are therefore 1.5× those figures at every step. Following those unit numbers with a 1.5 mL mix delivers two thirds of the named milligram dose. Restating the vial total as 10 mg rather than 5 mg does not remove this disagreement — it is a diluent-volume error in those tables, independent of how the vial mass is counted.
Titration: 0.25 mg weeks 1–4, 0.5 mg weeks 5–8, 0.75 mg weeks 9–12, 1 mg weeks 13–16, then weekly 0.25 mg increments as tolerated to a 2.5 mg maximum target. Doses refer to each component; the 1:1 ratio means they escalate together.
Mandatory low start regardless of prior GLP exposure — the constraint comes from the amylin arm, not the incretin arm, so tolerance built on a GLP does not transfer.
Storage: refrigerated, no freezing, up to 12 months shelf life properly stored.
The cagrilintide page's 12-week continuous-use cap and 46–73% anti-cagrilintide antibody rate are worth carrying over here: this blend's titration schedule runs past 16 weeks, which is longer than the standalone cagrilintide page permits for that component.
5/5 mg blend vial (10 mg total peptide)
Mix with 1.5 mL (150 units) of bacteriostatic water, giving 6.67 mg/mL of blend — 66.7 mcg of blended peptide per insulin unit, 33.3 mcg of each compound. The vial holds 10 mg of peptide in total, 5 mg of each. The titration figures are per component, so the doses below are the total blend drawn (twice the per-component figure named in the row label). Note on the draw figures: unit tables showing 5 units = 0.25 mg correspond to 5 mg in a 1 mL mix, not the 1.5 mL used here; at 1.5 mL, 0.25 mg of each compound is 7.5 units, not 5. The draws below are computed from the stated 1.5 mL and are therefore 1.5× those tables' numbers at every step.
6.67 mg/mL · 66.67 mcg per unit
Cycle: Titration runs at least 16 weeks; the standalone Cagrilintide page caps that component at 12 consecutive weeks · Frequency: Once weekly, subcutaneous, same day each week. Start at the lowest dose even if transferring from GLP1-S or another GLP
| When | Dose | Draw | How often |
|---|---|---|---|
| Weeks 1–4 — 0.25 mg of each compound (0.5 mg of blend drawn) | 500 mcg | 7.5 units | once weekly |
| Weeks 5–8 — 0.5 mg of each compound (1 mg of blend drawn) | 1 mg | 15 units | once weekly |
| Weeks 9–12 — 0.75 mg of each compound (1.5 mg of blend drawn) | 1.5 mg | 22.5 units | once weekly |
| Weeks 13–16 — 1 mg of each compound (2 mg of blend drawn) | 2 mg | 30 units | once weekly |
| Then increase weekly as tolerated in 0.25 mg steps up to the 2.5 mg maximum target dose of each compound (5 mg of blend drawn) | 5 mg | 75 units | once weekly |
10 mg of blend in 1.5 mL is 6.67 mg/mL, or 66.67 mcg per unit. Draw 7.5 units (0.075 mL) for 500 mcg of blend.
- GLP1-S250 mcg
- Cagrilintide250 mcg
Who should avoid it
- Anyone with a personal or family history of medullary thyroid carcinoma (MTC) — a cancer of specific hormone-producing cells in the thyroid — or of MEN2, an inherited condition that raises the risk of tumours in several hormone glands.
- Anyone allergic or hypersensitive to any of its components.
- Anyone with a history of pancreatitis, meaning inflammation of the pancreas.
- Anyone pregnant or breastfeeding.
- Anyone currently using another GLP-1 drug, including microdoses.
- Use with caution if you have reduced kidney function.
- Use with caution if you have unstable heart or circulatory disease.
- Use with caution if you have gastroparesis — stomach paralysis — or another condition that slows the movement of food through the gut.
- Personal or family history of medullary thyroid carcinoma or MEN2.
- Allergy or hypersensitivity to any component.
- History of pancreatitis.
- Pregnancy or breastfeeding.
- Concurrent use of another GLP-1 drug, microdoses included — receptor redundancy on the GLP-1 arm.
- Caution: renal dysfunction.
- Caution: cardiovascular instability.
- Caution: gastroparesis or other GI motility disorders — the blend delays gastric emptying from both arms.
Side effects
- Most side effects are temporary and similar to other GLP-1 medications.
- Nausea.
- Vomiting.
- Constipation or diarrhoea.
- Headache.
- Abdominal discomfort.
- Injection site irritation.
- Generally transient and comparable to the GLP-1 class.
- Nausea.
- Vomiting.
- Constipation or diarrhoea.
- Headache.
- Abdominal discomfort.
- Injection site irritation.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
- Glutathione
Supports liver detoxification, blood sugar balance, and reduces oxidative stress — damage to cells from unstable molecules.
Hepatic detoxification support with glycaemic balance and reduction of oxidative stress.
- Vitamin B12 or MIC+C
Enhances energy, combats fatigue, and supports fat metabolism. This matters especially while eating far less than usual.
Energy and fat-metabolism support, particularly relevant under caloric restriction.
May amplify appetite suppression and support the brain's dopamine-based reward pathways.
Amplifies appetite suppression and adds dopaminergic reward-pathway modulation — a different lever on intake than either component of the blend.
Growth hormone secretagogues, meaning compounds that make your body release its own growth hormone. They preserve muscle mass and support metabolic health during fat loss.
GH secretagogue pairing for lean mass preservation and metabolic support through the deficit.
- Thymosin Alpha-1
Supports immune balance in people with metabolic or inflammatory conditions.
Immune modulation, aimed at users with metabolic or inflammatory comorbidity.
Worth reading if you plan to use this blend long term. The standalone Cagrilintide page caps continuous use of that component at 12 weeks, which is shorter than this blend's full titration schedule.
The standalone page's constraints apply to the amylin component here: 12-week continuous-use cap, 46–73% anti-cagrilintide antibody formation on extended exposure. Separate vials allow the cagrilintide arm to be cycled independently of the GLP arm; the fixed blend does not.
Dosing figures have been reviewed and units are recomputed from the stated protocol.